Bg pattern

CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Carglumic Acid Waymade 200 mg Dispersible Tablets EFG

carglumic acid

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others, as it may harm them, even if their symptoms are the same as yours.
  • If you experience any of the side effects, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. See section 4.

In this leaflet:

  1. What Carglumic Acid is and what it is used for
  1. What you need to know before you take Carglumic Acid
  1. How to take Carglumic Acid
  1. Possible side effects
  • Storage of Carglumic Acid
  1. Further information

1. What Carglumic Acid is and what it is used for

The name of this medicine is Carglumic Acid Waymade 200 mg Dispersible Tablets. In this leaflet, it will be called Carglumic Acid.

Carglumic Acid can help eliminate high levels of ammonia in the blood. Ammonia is especially toxic to the brain and can cause, in severe cases, a decrease in the level of consciousness and coma.

Hyperammonemia can be due to

  • the lack of a specific liver enzyme (N-acetylglutamate synthase). Patients with this rare disorder are unable to eliminate nitrogen waste, which increases after eating proteins.

This disorder persists throughout the patient's life, so this treatment is necessary for life

  • isovaleric acidemia, methylmalonic acidemia, or propionic acidemia. Patients who suffer from one of these disorders need treatment during the hyperammonemia crisis.

.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you start taking Carglumic Acid

Do not take Carglumic Acid:

  • if you are allergic (hypersensitive) to carglumic acid or any of the other ingredients of this medicine (see section 6 for the complete list of ingredients).
  • during breastfeeding.

Warnings and precautions

Treatment with carglumic acid should be initiated under the supervision of a doctor with experience in the treatment of metabolic disorders.

Your doctor will evaluate your individual response to carglumic acid before starting any long-term treatment. The dose should be adjusted individually to maintain normal blood ammonia levels.

Your doctor may prescribe you arginine supplements or limit your protein intake.

In order to monitor your disease and treatment, your doctor may periodically examine your liver, kidneys, heart, and blood.

Use of other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.

Use of Carglumic Acid with food and drinks

Carglumic Acid should be taken orally before main meals or food intake.

The tablets should be dispersed in a minimum of 5 to 10 ml of water and taken immediately. The suspension has a slightly acidic taste.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before taking this medicine.

Pregnancy

The effects of carglumic acid on pregnancy and the fetus are unknown. Please consult your doctor if you are pregnant or plan to become pregnant.

Breastfeeding

You should not breastfeed your child if you take Carglumic Acid. It has not been studied whether carglumic acid passes into human breast milk. However, it has been shown that carglumic acid is present in the milk of lactating rats, with possible toxic effects on the suckling pups.

Driving and using machines

The effects on the ability to drive and use machines are unknown.

Carglumic Acid contains sodium.

The maximum recommended daily dose of this product contains 396 mg of sodium (main component of table salt/cooking salt). This is equivalent to 20% of the maximum recommended daily sodium intake for an adult.

Consult your doctor or pharmacist if you need 132 or more tablets per day for a prolonged period, especially if you have been recommended a low-salt (sodium) diet.

3. How to take Carglumic Acid

Follow exactly the administration instructions of this medicine indicated by your doctor. Consult your doctor or pharmacist if you have any doubts.

The usual dose:

The initial daily dose is usually 100 mg per kg of body weight, up to a maximum of 250 mg per kg of body weight (for example, if you weigh 10 kg, you should take 1 g per day, or 5 tablets).

For patients with N-acetylglutamate synthase deficiency, the long-term daily dose usually ranges from 10 mg to 100 mg per kg of body weight.

Your doctor will determine the suitable dose for you to maintain normal blood ammonia levels.

Carglumic Acid should be administered ONLY orally or through a nasogastric tube (using a syringe if necessary).

When the patient is in hyperammonemic coma, carglumic acid is administered by rapid administration with a syringe through the tube used for feeding.

Tell your doctor if you have kidney impairment. Your daily dose should be reduced.

If you take more Carglumic Acid than you should

If you accidentally take too many tablets, inform your doctor immediately or contact the nearest hospital. Bring the package and leaflet of the medicine with you.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91.562.04.20, indicating the medicine and the amount ingested

If you forget to take Carglumic Acid

If you forget to take a dose, take the next one at the usual time. DO NOT TAKE a double dose to make up for the missed individual dose.

If you stop taking Carglumic Acid:

Do not stop taking carglumic acid without informing your doctor.

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, Carglumic Acid can cause side effects, although not everybody gets them.

The following side effects have been reported:

  • Common (may affect up to 1 in 10 people):increased sweating
  • Uncommon (may affect up to 1 in 100 people):decreased heart rate, diarrhea, fever, vomiting, increased aminotransferases (enzymes that may indicate liver damage)
  • Frequency not known: skin rash.

If you experience any of the side effects, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects

If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Carglumic Acid

Keep out of sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton, blister or bottle after EXP. The expiry date is the last day of the month shown.

Bottle

This medicine does not require any special storage conditions.

After opening the tablet container for the first time: do not refrigerate or freeze. Discard 1 month after first opening.

Keep the container tightly closed to protect it from moisture.

Blister

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. This will help to protect the environment.

6. Further information

Composition of Carglumic Acid

  • The active substance is carglumic acid. Each tablet contains 200 mg of carglumic acid.
  • The other ingredients are microcrystalline cellulose, sodium croscarmellose, sodium lauryl sulfate, anhydrous colloidal silica, and sodium stearyl fumarate.

Appearance and packaging of the product

Carglumic Acid Waymade 200 mg Dispersible Tablets are white or almost white, bar-shaped tablets, 18 mm x 6 mm, with 3 break lines on both sides and engraved with "N" on one side.

The tablets can be divided into equal doses.

Carglumic Acid is available in plastic containers or blister packs of 5, 15, and 60 tablets.

Not all pack sizes may be marketed.

Marketing authorisation holder

Waymade B.V.

Herikerbergweg 88,

1101 CM Amsterdam,

Netherlands

Manufacturer

Drehm Pharma GmbH

Grünbergstraße 15/3/3,

1120 Wien

Austria

or

Waymade B.V.

Herikerbergweg 88,

1101 CM Amsterdam,

Netherlands

You can obtain further information on this medicine by contacting the local representative of the Marketing Authorisation Holder.

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid

Spain

Date of last revision of this leaflet:August 2024

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS): http://www.aemps.gob.es/.

Online doctors for CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS

Discuss questions about CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS?
CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS?
The active ingredient in CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS is carglumic acid. This information helps identify medicines with the same composition but different brand names.
Who manufactures CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS?
CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS is manufactured by Waymade B.V.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to CARGLUMIC ACID WAYMADE 200 mg DISPERSIBLE TABLETS?
Other medicines with the same active substance (carglumic acid) include CARGLUMIC ACID TILLOMED 200 mg DISPERSIBLE TABLETS, CARBAGLU 200 mg DISPERSIBLE TABLETS, CARBAGLU 200 mg DISPERSIBLE TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media